Silence Therapeutics to discuss Phase 2 divesiran trial results
Silence Therapeutics plc (Nasdaq: SLN) announced it will host a conference call and ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
